We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PAHC Stock: What's Driving Phibro's Animal Health Growth
Read MoreHide Full Article
Key Takeaways
PAHC's Animal Health segment generated 74% of fiscal 2025 revenue and grew 36% from fiscal 2024.
Phibro's Q3 fiscal 2026 Animal Health sales rose 13% to $291.2M, aided by MFA and vaccine growth.
PAHC raised fiscal 2026 outlook to $1.46B-$1.50B sales and $247M-$255M adjusted EBITDA.
Phibro Animal Health Corporation (PAHC - Free Report) is drawing investor attention because its growth story is increasingly tied to Animal Health, the company’s largest and most strategically important business. The segment now anchors the revenue base, while vaccines, medicated feed additives (MFA) and nutritional specialties give Phibro multiple avenues for expansion.
The stock’s near-term setup depends on whether this segment can keep offsetting risks from regulation, currency swings and uneven demand in smaller businesses.
Here’s a look at Phibro’s stock performance over the past 12 months.
Image Source: Zacks Investment Research
PAHC’s Growth Engine Inside Animal Health
Animal Health accounted for 74% of Phibro’s total revenues in fiscal 2025, making it the company’s clear growth engine. The segment grew 36% from fiscal 2024, reflecting the strength of a broader product platform across MFAs, nutritional specialty products and vaccines. The company develops, manufactures and markets more than 550 product presentations in this business, giving it a wide base of customers and species exposure.
For investors, the focus is simple. If Animal Health continues to grow, it can help Phibro absorb volatility in Mineral Nutrition and Performance Products while supporting a higher-quality earnings base.
Phibro’s MFA Franchise Gets a Bigger Runway
Phibro’s MFA franchise remains central to the Animal Health story, with its leading Stafac/V-Max/Eskalin platform is approved in more than 30 countries. The integration of Zoetis Inc.’s (ZTS - Free Report) MFA business has brought more than 37 established product lines marketed across approximately 80 countries, along with six manufacturing sites in the United States, Italy and China.
That broader footprint expands Phibro’s ability to serve customers across regions and supports a larger recurring revenue base. This added scale is important because it does not rely on a single product or geography.
PAHC’s Q3 Segment Mix Shows the Momentum
The fiscal third-quarter 2026 results showed how that platform is translating into revenue momentum. Animal Health net sales increased 13% year over year to $291.2 million, ahead of the internal model projection of $265.7 million.
The acquired MFA business generated a full quarter of revenues and grew 25% over the prior-year period. Legacy MFA sales increased 5%, helped by demand in North America and certain antimicrobials sold by the Ethanol Performance business. Nutritional specialty product sales rose 8% on higher North America demand and higher companion animal sales.
Vaccines net sales were up 16% year over year. That segment mix supported management’s updated fiscal 2026 outlook, including net sales of $1.46 billion to $1.50 billion and adjusted EBITDA of $247 million to $255 million.
Phibro’s Vaccines Add a Differentiated Growth Vector
Phibro’s vaccine business gives Animal Health a growth avenue that differs from mature feed additive categories. In fiscal third-quarter 2026, vaccine sales rose 16%, driven by higher international demand, including Israel, along with stronger domestic swine demand and increased sales of autogenous vaccines.
The business includes approximately 50 product lines for poultry disease prevention, covering areas such as Infectious Bursal Disease, Infectious Bronchitis, Newcastle Disease, Reovirus, Salmonella and Coryza. As disease pressures shift, vaccines can become a more differentiated part of the portfolio because they are less exposed to generic competition than some feed additive categories.
Phibro is also investing in vaccine manufacturing capacity, including its production facility in Guarulhos, Brazil. That capacity expansion supports volume growth and broader access across geographies.
PAHC’s Global Footprint Helps Smooth Species Cycles
Phibro’s international reach adds another layer to the Animal Health case. The company markets nearly 770 product lines in more than 80 countries to about 4,000 customers, with operations focused on regions where livestock production is concentrated in large commercial farms.
That strategy supports product adoption and recurring demand. In fiscal third-quarter 2026, net sales rose 14% year over year in Europe, the Middle East and Africa, 9% in Asia Pacific, and 7% in Latin America and Canada.
Take a look at Phibro’s valuation.
Image Source: Zacks Investment Research
Large peers such as Zoetis and Merck & Co., Inc. (MRK - Free Report) also show how broad animal health platforms can benefit from scale, product depth and geographic reach, though Phibro’s mix remains more concentrated around its own feed additive, vaccine and nutrition strengths.
Phibro’s Outlook Balances Tailwinds With Known Risks
Phibro’s Health growth is being supported by the Zoetis MFA portfolio, steady legacy demand and higher vaccine volumes. Management also raised the low end of full-year expectations, a sign that recent execution has improved visibility. Yet, Brazil’s antimicrobial transition creates uncertainty for virginiamycin and bacitracin, while Mecadox remains under regulatory and legal scrutiny. Foreign exchange can also add earnings volatility, with fiscal third-quarter results including $1.9 million of foreign currency losses. Competition is another factor.
PAHC carries a Zacks Rank #2 (Buy), but the path is likely to remain uneven if Brazil disruption, currency pressure or generic competition weigh on the Animal Health growth engine.
View the Zacks #1 Rank List
Image: Bigstock
PAHC Stock: What's Driving Phibro's Animal Health Growth
Key Takeaways
Phibro Animal Health Corporation (PAHC - Free Report) is drawing investor attention because its growth story is increasingly tied to Animal Health, the company’s largest and most strategically important business. The segment now anchors the revenue base, while vaccines, medicated feed additives (MFA) and nutritional specialties give Phibro multiple avenues for expansion.
The stock’s near-term setup depends on whether this segment can keep offsetting risks from regulation, currency swings and uneven demand in smaller businesses.
Here’s a look at Phibro’s stock performance over the past 12 months.
Image Source: Zacks Investment Research
PAHC’s Growth Engine Inside Animal Health
Animal Health accounted for 74% of Phibro’s total revenues in fiscal 2025, making it the company’s clear growth engine. The segment grew 36% from fiscal 2024, reflecting the strength of a broader product platform across MFAs, nutritional specialty products and vaccines. The company develops, manufactures and markets more than 550 product presentations in this business, giving it a wide base of customers and species exposure.
For investors, the focus is simple. If Animal Health continues to grow, it can help Phibro absorb volatility in Mineral Nutrition and Performance Products while supporting a higher-quality earnings base.
Phibro’s MFA Franchise Gets a Bigger Runway
Phibro’s MFA franchise remains central to the Animal Health story, with its leading Stafac/V-Max/Eskalin platform is approved in more than 30 countries. The integration of Zoetis Inc.’s (ZTS - Free Report) MFA business has brought more than 37 established product lines marketed across approximately 80 countries, along with six manufacturing sites in the United States, Italy and China.
That broader footprint expands Phibro’s ability to serve customers across regions and supports a larger recurring revenue base. This added scale is important because it does not rely on a single product or geography.
PAHC’s Q3 Segment Mix Shows the Momentum
The fiscal third-quarter 2026 results showed how that platform is translating into revenue momentum. Animal Health net sales increased 13% year over year to $291.2 million, ahead of the internal model projection of $265.7 million.
The acquired MFA business generated a full quarter of revenues and grew 25% over the prior-year period. Legacy MFA sales increased 5%, helped by demand in North America and certain antimicrobials sold by the Ethanol Performance business. Nutritional specialty product sales rose 8% on higher North America demand and higher companion animal sales.
Vaccines net sales were up 16% year over year. That segment mix supported management’s updated fiscal 2026 outlook, including net sales of $1.46 billion to $1.50 billion and adjusted EBITDA of $247 million to $255 million.
Phibro’s Vaccines Add a Differentiated Growth Vector
Phibro’s vaccine business gives Animal Health a growth avenue that differs from mature feed additive categories. In fiscal third-quarter 2026, vaccine sales rose 16%, driven by higher international demand, including Israel, along with stronger domestic swine demand and increased sales of autogenous vaccines.
The business includes approximately 50 product lines for poultry disease prevention, covering areas such as Infectious Bursal Disease, Infectious Bronchitis, Newcastle Disease, Reovirus, Salmonella and Coryza. As disease pressures shift, vaccines can become a more differentiated part of the portfolio because they are less exposed to generic competition than some feed additive categories.
Phibro is also investing in vaccine manufacturing capacity, including its production facility in Guarulhos, Brazil. That capacity expansion supports volume growth and broader access across geographies.
PAHC’s Global Footprint Helps Smooth Species Cycles
Phibro’s international reach adds another layer to the Animal Health case. The company markets nearly 770 product lines in more than 80 countries to about 4,000 customers, with operations focused on regions where livestock production is concentrated in large commercial farms.
That strategy supports product adoption and recurring demand. In fiscal third-quarter 2026, net sales rose 14% year over year in Europe, the Middle East and Africa, 9% in Asia Pacific, and 7% in Latin America and Canada.
Take a look at Phibro’s valuation.
Image Source: Zacks Investment Research
Large peers such as Zoetis and Merck & Co., Inc. (MRK - Free Report) also show how broad animal health platforms can benefit from scale, product depth and geographic reach, though Phibro’s mix remains more concentrated around its own feed additive, vaccine and nutrition strengths.
Phibro’s Outlook Balances Tailwinds With Known Risks
Phibro’s Health growth is being supported by the Zoetis MFA portfolio, steady legacy demand and higher vaccine volumes. Management also raised the low end of full-year expectations, a sign that recent execution has improved visibility. Yet, Brazil’s antimicrobial transition creates uncertainty for virginiamycin and bacitracin, while Mecadox remains under regulatory and legal scrutiny. Foreign exchange can also add earnings volatility, with fiscal third-quarter results including $1.9 million of foreign currency losses. Competition is another factor.
PAHC carries a Zacks Rank #2 (Buy), but the path is likely to remain uneven if Brazil disruption, currency pressure or generic competition weigh on the Animal Health growth engine.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.